ABCL
NASDAQ · Life Sciences Tools & Services
Abcellera Biologics Inc
$11.88
+0.75 (+6.74%)
Financial Highlights (FY 2026)
Revenue
81.50M
Net Income
-158,848,014
Gross Margin
—
Profit Margin
-194.9%
Rev Growth
-46.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 45.4% | 45.4% |
| Operating Margin | -289.0% | -260.1% | 15.2% | 17.5% |
| Profit Margin | -194.9% | -185.1% | 11.0% | 10.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 81.50M | 151.79M | 396.65M | 320.81M |
| Gross Profit | — | — | 180.20M | 145.75M |
| Operating Income | -235,512,660 | -394,787,472 | 60.29M | 56.27M |
| Net Income | -158,848,014 | -266,275,307 | 43.78M | 34.81M |
| Gross Margin | — | — | 45.4% | 45.4% |
| Operating Margin | -289.0% | -260.1% | 15.2% | 17.5% |
| Profit Margin | -194.9% | -185.1% | 11.0% | 10.9% |
| Rev Growth | -46.3% | -46.3% | +18.5% | +8.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 222.59M | 227.01M |
| Total Equity | — | — | 817.40M | 806.57M |
| D/E Ratio | — | — | 0.27 | 0.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -211,473,305 | -374,184,465 | 99.33M | 83.21M |
| Free Cash Flow | — | — | 67.30M | 42.05M |